Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if belzutifan alone, pembrolizumab alone, or belzutifan and pembrolizumab in combination given before a total or partial nephrectomy (surgery to remove all or part of a kidney) can help to control locally advanced ccRCC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biopsją rak nerki typu jasnokomórkowego
- •Pośredni-wysoki, wysoki stopień zaawansowania lub przerzuty (M1)
- •Wiek co najmniej 18 lat
- •Dobry stan ogólny (ocena 0-1 w skali ECOG)
- •Brak przerzutów w płucach, brzuchu i miednicy w ciągu 42 dni przed zapisaniem
- •Zakwalifikowany przez urologa do operacji usunięcia nerki
- •Wystarczająca liczba białych krwinek (≥1000), płytek (≥75) i hemoglobiny (≥9)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The University of Texas M. D. Anderson Cancer Center
Houston, United States
Trial contact
Eric Jonasch, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.